Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1197-1201

  Wollina, Uwe ^a   Liebold, Kristin ^a   Kaatz, Martin ^a   Looks, Annette ^a   Stuhlert, Anselm ^a   Lange, Dirk ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photochemotherapy; Interferon ; Outcome

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PATHOLOGY; PROSPECTIVE STUDY; PUVA; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-ALPHA; LYMPHOMA, LARGE-CELL, KI-1; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PHOTOPHERESIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 0034323998     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1197     Document Type: Article

References (24)

1. Diamandidou E, Cohen PR and Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88: 2385-2409, 1996.
2. Lorincz A: Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 347: 871-876, 1996.
3. Sausville EA, Eddy JL, Makuch RW, et al: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 109: 372-382, 1988.
4. Kim YH, Jensen RA, Watanabe GL, Varghese A and Hoppe RT: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132: 1309-1313, 1996.
5. Bunn PA Jr, Hoffman SJ, Morris D, Golitz LE and Aeling JL: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121: 592-602, 1994.
6. Kaye FJ, Bunn PJ, Steinberg SM, et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321: 1784-1790, 1989.
7. Fierro MT, Quaglino P, Savoia P, Verrone A and Bernengo MG: Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 31: 583-588, 1998.
8. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparision of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
9. Edelson RL, Berger CL, Gasparro FP, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 316: 297-303, 1987.
10. Armus S, Keyes B, Cahill C, et al: Photopheresis for the treatment of cutaneous T cell-lymphoma. J Am Acad Dermatol 23: 898-902, 1990.
11. Lim HW and Edelson RL: Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9: 1117-1126, 1995.
12. Gottlieb SL, Wolfe JT, Fox FE, et al: Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 35: 946-957, 1996.
13. Dippel E, Schrag H, Goerdt S and Orfanos CE: Extracorporeal photopheresis and interferon-α in advanced T-cell lymphoma. Lancet 350: 32-33, 1997.
14. Wollina U, Graefe T and Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42: 40-46, 2000.
15. Burg G, Dummer R and Kerl H: Classification of cutaneous lymphomas. Dermatol Clin 12: 1115-1122, 1994.
16. Kerl H and Sterry W: Classification and staging. In: EORTC/ BMFT Cutaneous Lymphoma Project Group: Recommendations for Staging and Therapy of Cutaneous Lymphomas. Burg G and Sterry W (eds). Springer, Berlin, ppl-10, 1987.
17. Cheson BD, Horning SJ, Coiffier B, et al: Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244-1253, 1999.
18. Seegenschmiedt MH: Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 174 (Suppl. 3): 25-29, 1998.
19. Wiernik PH, Moore DF, Bennett JM, et al: Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481). Leuk Lymphoma 30: 601-607, 1998.
20. Duvic M, Hester JP and Lemak NA: Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 35: 573-579, 1996.
21. Ross C, Tingsgaard P, Jorgensen H and Vejlsgaard GL: Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51: 63-72, 1993.
22. Vegna ML, Papa G, Defazio D, et al. Interferon in the treatment of mycosis fungoides (MF). Haematologica 72: 337-340, 1990.
23. Springer EA, Kuzel TM, Variakojis D, Kaul K, Rosen ST and Roenigk HH Jr: Correlation of clinical responses with immunologie and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon α-2a. J Am Acad Dermatol 29: 42-46, 1993.
24. Zic JA, Stricklin GP, Greer JP, Kinney MC, Shyr Y, Wilson DC and King LE Jr: Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 35: 935-945, 1996.